🔗 Share this article

A shadow economy for unlicensed weight-loss drugs is being driven by social media fitness personalities and sellers on messaging platforms, according to new investigations.

Experimental Drug Gaining Popularity Via Social Media

Retatrutide, which is still in clinical trials, is being advertised by social media influencers for its alleged weight-reducing properties. Viewers are urged to message these profiles directly for source information, while also receiving promotional offers.

Active Commerce on Messaging Platforms

Separately, a flourishing market exists on messaging services, where communities with thousands of members share comparison photos, injection guides and assertions of next-day British shipping. Vendors market the substance there before directing customers to other platforms for purchases.

Learning About The Experimental Drug

This medication is an investigational injectable created by American pharmaceutical company Eli Lilly. The treatment targets three gut hormones – GLP-1, GIP and pancreatic hormone. Preliminary studies suggest it could help individuals lose up to 25% of their body weight. Nicknamed the “triple G”, the substance is being promoted online as the next Ozempic.

Medical Experts Express Concerns

However, physicians and chemists have warned that the distribution of what is still an unapproved medication in the UK is a cause for concern and could result in individuals injecting products of unknown origin.

Some professionals stated the demand for the experimental drug could be connected to the rising cost of approved slimming products such as Mounjaro.

Legal Status and Implementation

Marketing the unapproved drug on social media or messaging apps is illegal in the United Kingdom, as it is an unapproved medication that must not be promoted or supplied for human use under the British medical regulations.

Several influencers attempt to sidestep the regulations by calling to the drug as a “research chemical” or describing it as “not for human consumption”. The substance is not a controlled substance, but advertising and supply can still breach medicines, advertising, and customer regulations, risking fines, prosecution or prison.

Service Reaction and Content Elimination

Based on the social media company, the platform has removed violative material and prohibited related keywords and search suggestions. The company said it was committed to maintaining the service safe and investing in strengthening enforcement strategies.

Online Trading Activities

Research also found groups with up to 9,000 members marketing retatrutide using the platform's integrated discovery tool, which functions like a online catalog. Typing “retatrutide” instantly displays groups with thousands of users, populated with photos of weight loss, positive testimonials and step-by-step guides for preparing or administering at home.

Within moments of joining one community, a vendor shared contact information, where the majority of transactions take place. The vendor provided an instruction manual and guaranteed shipping within 48 hours. When asked whether the product was genuine, one vendor said: “You can’t be sure.” Another provided a photo of a supposed laboratory certificate. Not one inquired about body mass, medical conditions or past usage.

Product Information and Pricing

Within these groups, messages display dark colored packages with postal service labels, claiming to include fresh supplies. One message stated: “It took eight of us to load them this morning.”

Customers can choose between powder vials, prepared at home with sterile water, or pre-filled injectors usually priced at £160 for 20 milligrams. When questioned how much time a pen should last, vendors give contradictory answers ranging from a several days to “depends on your body”.

Service Oversight and Security Actions

A spokesperson for the messaging service stated it actively monitored dangerous content on its service including content that promoted the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.

Healthcare Expert Warnings

“People are injecting substances they can’t verify. Although the science behind this drug is sound, these online versions may not contain what they claim,” said a pharmacy expert, the director of pharmaceutical services at a pharmacy service.

Dr Crystal Wyllie of Asda Online Doctor linked the surge in interest to recent price rises for authorized weight-loss drugs such as Mounjaro. “With costs rising, individuals are turning to social media. But counterfeit treatments are extremely risky. You can’t be certain what’s inside or whether the conditions they were made in was sterile,” she said.

Her staff has already encountered individuals harmed by self-injection from unverified suppliers. “We understand the frustration, but buying from messaging apps or communication platforms is gambling with your well-being,” said the doctor. “These materials could be impure or improperly measured.”

Producer Statement

A spokesperson from the pharmaceutical company said retatrutide was in phase 3 research studies and had not been reviewed or authorized by any government authority anywhere in the world. “Consequently at this point no one can market [it] for personal consumption,” they explained, noting that any item “misleadingly claiming itself as a Lilly experimental product not yet authorized … may subject users to potentially serious health risks”.